What medications should be stopped or adjusted while taking Paxlovid (nirmatrelvir and ritonavir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications to Stop or Adjust While Taking Paxlovid

Yes, multiple medications must be stopped or adjusted before and during Paxlovid treatment due to ritonavir's potent inhibition of CYP3A4 enzymes, which can cause life-threatening drug interactions. 1

Medications That Must Be Stopped (Contraindicated)

Statins

  • Lovastatin and simvastatin must be discontinued at least 12 hours before starting Paxlovid due to severe risk of rhabdomyolysis 2, 3, 1
  • Atorvastatin should be temporarily discontinued during the 5-day treatment course (no pre-treatment washout needed) 1

Cardiovascular Medications

  • Amiodarone is contraindicated due to risk of life-threatening cardiac arrhythmias 4, 2, 3, 1
  • Alfuzosin, dronedarone, flecainide, propafenone, quinidine, ranolazine, and ivabradine must be avoided 1
  • Eplerenone is contraindicated due to hyperkalemia risk 1

Sedatives and Antipsychotics

  • Oral midazolam and triazolam are contraindicated due to prolonged sedation and respiratory depression risk 2, 3, 1
  • Quetiapine must be avoided or significantly dose-reduced due to marked toxicity risk 2, 3, 1
  • Lurasidone and pimozide are contraindicated due to cardiac arrhythmia risk 1

Ergot Derivatives

  • Dihydroergotamine, ergotamine, and methylergonovine are contraindicated due to acute ergot toxicity causing vasospasm and ischemia 3, 1

Pulmonary Medications

  • Sildenafil (when used for pulmonary arterial hypertension) is contraindicated due to excessive vasodilation 3, 1
  • Salmeterol must be avoided due to serious cardiovascular adverse events 3

Strong CYP3A4 Inducers (Must Stop Well Before Paxlovid)

These medications significantly reduce Paxlovid effectiveness and cannot be started immediately after discontinuation:

  • Rifampin and rifapentine (antimycobacterials) 3, 1
  • Carbamazepine, phenytoin, phenobarbital, primidone (anticonvulsants) 1
  • St. John's Wort (herbal product) 2, 3, 1
  • Enzalutamide and apalutamide (anticancer drugs) 2, 1

Medications Requiring Dose Adjustment or Temporary Hold

Immunosuppressants (Highest Risk)

  • Tacrolimus should be discontinued or given as a microdose on day 1 only during Paxlovid treatment due to severe toxicity risk 5, 6
  • Cyclosporine dose should be reduced to 20% of baseline 5
  • Voclosporin is contraindicated due to nephrotoxicity 1
  • Everolimus and sirolimus should be avoided 1

Anticoagulants

  • Rivaroxaban and apixaban require dose reduction (25% for apixaban) with close bleeding monitoring 3, 7
  • Warfarin requires dose reduction by 50% with INR monitoring 4, 7

Calcium Channel Blockers

  • Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, and verapamil require dose reduction and clinical monitoring 1, 7

Other Medications Requiring Adjustment

  • Digoxin requires dose reduction by 30-50% with serum level monitoring 4, 1
  • Colchicine is contraindicated in patients with renal or hepatic impairment 1
  • Saxagliptin and tofacitinib require dose adjustments per product labels 1

Hormonal Contraceptives

  • Ethinyl estradiol effectiveness is reduced; use additional non-hormonal contraception during treatment and until one menstrual cycle after completion 1

Critical Management Recommendations

Before prescribing Paxlovid, conduct a comprehensive medication review using drug interaction databases (such as the Liverpool COVID-19 Drug Interaction tool) 2, 8

Common Pitfalls to Avoid:

  • Do not assume short-term ritonavir exposure is safe—even 5 days can cause severe toxicity with narrow therapeutic index drugs 5, 8
  • Remember that CYP3A4 inducers have delayed offset; stopping them immediately before Paxlovid is insufficient 1
  • Immunosuppressant interactions are particularly dangerous in transplant patients and require expert consultation 1, 5
  • Multiple case reports document tacrolimus toxicity presenting as generalized weakness in emergency departments 6

The risk-benefit analysis must weigh potential drug interactions against the benefit of preventing severe COVID-19, particularly in high-risk patients 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.